Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Recruiting

Phase 1

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Sponsor:

National Cancer Institute (NCI)

Code:

NCT04609046

Conditions

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bone Marrow Aspiration and Biopsy

Computed Tomography

Echocardiography Test

Lenalidomide

Lumbar Puncture

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-01.